

Table S1 Preoperative systemic treatment for CRLM patients (n=127)

	N (%)	Cycles number, median (range)
Chemotherapy		
FOLFOX	48 (37.8)	8 (4–18)
FOLFIRI	20 (15.7)	8 (4–24)
FOLFIRINOX	40 (31.5)	6 (1–25)
NA	19 (15.0)	–
Targeted therapies		
Bevacizumab	44 (34.6)	7 (4–18)
Cetuximab	19 (14.9)	9 (5–15)
Panitumumab	18 (14.1)	6 (3–17)

CRLM, colorectal liver metastasis; NA, not available.